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2Deadly Discounts: How Reimportation Jeopardizes the Safety of the U.S. Pharmaceutical 
Drug Supply under the Federal Trade Commission Amendment
By Nicole Bates
Summary
This paper analyzes a pharmaceutical reimportation amendment not yet up for 
vote in the U.S. Congress. The amendment to a Federal Trade Commission (FTC) 
reauthorization bill, previously introduced as Senate Bill 334 (S.334) Pharmaceutical 
Market Access and Drug Safety Act of 2005 allows for the reimportation of prescription 
drugs into the United States from approximately 25 countries, including Canada via 
Internet pharmacies.  There are no guarantees that the internet websites advertising as 
Canadian pharmacies are legitimate.  The shipping of pharmaceutical drugs occurs 
through importation, which refers to drugs produced abroad then later shipped to the 
U.S., or re-importation, a term applied when drugs are produced in the U.S. and exported 
for sale to foreign countries and later imported back into the U.S.  
The amendment attempts to open the border doors even further by allowing 
increased importation of medicine and requires pharmacies and drug wholesalers to 
register with the FDA.  The potential importers will be subject to frequent, random 
inspection; however, these inspections are inadequate and more must be done.  Some real 
solutions include electronic pedigrees and authentication technologies.  Also, technology 
must be rotated so that illegitimate manufacturers can not adapt and overcome anti-
counterfeiting measures.  
3I. Introduction
Across the world, people get sick everyday.  From the common cold to cancer
treatment, people seek medicines that will ease their pain and suffering.  But what 
happens when those medicines we rely on to relieve our symptoms, in turn, actually end 
up causing more side effects?  Is there a way to actually know whether your medicine is 
real or a fraud? 
An amendment to the Federal Trade Commission (FTC), formerly known as 
Senate Bill (S.334) Pharmaceutical Market Access and Drug Safety Act of 2005, brings 
this issue to the forefront.  Supporters of the amendment argue that since the price of U.S. 
prescription drugs are rapidly increasing, citizens should be allowed to look outside of the 
country for cheaper alternatives.  The U.S. Congress found that senior citizens will spend 
$1,800,000,000,000 on pharmaceuticals over the next ten years.  Therefore, lawmakers 
can give foreign pharmaceutical markets the chance to offer U.S. citizens cheaper 
alternatives.1  Research shows that the average brand name drug in Canada is 38% 
cheaper than it would be if bought in the U.S.2
This sounds great of course.  Nobody would argue there is a problem with saving 
money.  However, the problem arises when the discount may cost people their lives.  
Congress argues that allowing medicine from outside markets into our country could save 
American consumers at least $38,000,000,000 each year.3  There is no denying that the 
cost of medicine is high in the United States, largely due to the fact price controls are 
1 Pharmaceutical Market Access and Drug Safety Act of 2005, S.334, 109th Cong. §2(5) [hereinafter 
known as S.334].
2
 Abraham N. Saiger, In Search of a Government that Will Govern: Senate Bill 812 and “Reimporting” 
Prescription Medication from Canada, 12 Elder L.J. 177, 179 (2004)(discussing the current state of affairs 
of medication prices in both the U.S. and Canada).
(citing Press Release, Office of Sen. Dorgan (D-N.D.), U.S. Consumers Pay Substantially Higher Prices for 
Their Medications than Consumers in Canada and Other Countries).
3
 S.334 supra note 1, at §2(6) .
4non-existent; but, the question then becomes, do people want to pay the high price for 
medicine or would they rather risk opening the floodgates of weakly regulated drugs into 
our country?  Which is the better choice of the two evils?  
The amendment, not yet up for Congressional vote, attempts to prevent 
counterfeit drugs from entering the U.S.  One method of regulation is requiring monthly 
inspections of imported medicines.  This is a positive step but more must be done to
adequately address the problem.  Currently, the amendment actually allows more 
medicine to enter into the country because more than 25 countries would be allowed to 
import medicine into the U.S.  The medicines from outside the U.S. cannot be guaranteed 
under FDA standards, thus, increasing the likelihood of fakes entering our healthcare 
system.  Several other problems remain and are discussed below. 
The topic of counterfeit medicines is new and evolving everyday with cases of 
fake medicines found in many countries throughout the world.  This paper will introduce 
the major topic areas and analyze the amendment attempts to combat this growing 
problem in the U.S.  This article will also take the position that the amendment should not 
be passed by Congress.  Instead, Congress needs to take a serious look at the multiple 
risks associated with reimportation and incorporate more safety features into a new bill.
II.  Reimportation
Reimportation is the practice of importing pharmaceutical drugs across the border 
from Canada4.  The majority of the drugs are manufactured originally in the United States 
4
 Jennifer L. Halser, Canadian Pharmacies: A Prescription for a Public Health Disaster, 54 DePaul L.Rev 
543, 544 (2005) (explaining the practice of reimportation)[hereinafter Halser].
5by U.S. pharmaceutical companies and then distributed to Canadian pharmacies5.  
Reimportating prescription drugs from Canada is currently illegal but is quickly 
becoming popular with U.S. citizens, especially the elderly6.
Approximately one million Americans cross the Canadian border annually to buy 
prescription drugs at low prices7.  Others visit Canadian pharmacies via the Internet or 
frequent U.S. stores like Rx Depot, Inc. that sell imported Canadian drugs at Canadian 
prices across the United States8.  In 2003, the amount of reimportation activity was 
predicted to be worth $800 million9.  Consumers can save between 32% and 57% on 
commonly purchased prescription drugs when purchasing them from Canadian 
pharmacies10.
The FDA has “enforcement discretion” which permits reimportation as outlined in 
the FDA’s Coverage of Personal Importations document11.  The FDA can and has 
allowed individual patients to import small prescriptions of drugs when the drug is not
available in the U.S.12 However, reimportation is not allowed under most circumstances,
and the FDA has sent warning letters to Canadian pharmacies yet only one Canadian 
pharmacy, Rx Depot, Inc., has been shut down13.
Despite the regulations on reimportation, politicians are beginning to create 
reimportation programs for their constituents and are already importing in record 
5 Id.
6
 Id.
7
 Chad D. Silker, America’s New War on Drugs: Should the United States Legalize Prescription Drug 
Reimportation?, 31 J. Legis 379, 379 (2005) (discussing the many forms of reimportation) [hereinafter 
Silker].
8
 Id.
9
 Halser, supra note 4.
10
 Id.
11
 Silker, supra note 7, at 383.
12
 Id.
13
 Halser, supra note 4, at 545.
6numbers14.  At the center of the reimportation issues is the amendment to the FTC 
reauthorization bill discussed in Section IV.  There are very serious problems and 
consequences that come with reimportation since the supply chain is not always clear and 
safe.  The medicine supposedly from Canada can come from anywhere, and U.S. citizens 
must be informed about all the risks involved with reimportation.  At the forefront of 
those risks, is the chance medicine entering the U.S. is counterfeit.
III.  Counterfeiting:  What is it?
Counterfeit medicines are deliberately and fraudulently mislabeled medicines as
to identity and/or source.15  Production, distribution, and sale of counterfeit medicines 
have all substantially increased in recent years.16 Annual earnings from counterfeit and 
substandard medicine sales are over $32 billion globally.17 Yet, this number may be even
larger since no global study has ever been conducted.18
By contrast, genuine medicines are medicines with correct packaging and the 
correct quantity of ingredients.19 Substandard medicines have genuine packaging but 
contain an incorrect quantity of ingredients (not deliberate).20  Counterfeit medicines are 
the result of any of the following: mislabeling drugs (such as a fake expiration date), no 
14
 Halser, supra note 4, at 545.
15
 World Health Organization, Regional Office for the Western Pacific, available at 
http://www.wpro.who.int/health_topics/counterfeit_medicines/general_info.htm (last visited July 19, 
2005)[hereinafter known as WHO Regional Office].
16 Id.
17 World Health Organization Media Centre: Substandard and Counterfeit Medicine, available at 
http://www.who.int/mediacentre/factsheets/fs275/en/index.html (last visited on May 18, 2005) [hereinafter 
WHO Media Centre].
18
 World Health Organization, Essential Drugs and Medicines Policy: Counterfeit Medicines: Overview 
available at 
http://www.who.int/medicines/organization/qsm/activities/qualityassurance/cft/CounterfeitOverview.htm
(last visited on July 27, 2005).
19
 WHO Regional Office, supra note 15.
20
 Id.
7active ingredients, wrong ingredients, correct ingredient and insufficient quantity of 
correct ingredients.21 Both brand name and generic products can be counterfeited.22
An example of counterfeit medicine was reported to the World Health 
Organization in 2002 when bottles of the HIV drug Combivir were found to actually 
contain another HIV medicine, Ziagen.23 This type of counterfeiting could have caused 
potentially life-threatening hypersensitivity reactions to HIV patients unaware of what 
they were taking since there was a possibility of deadly drug interactions with other 
medicines the patients were taking.24
A.  Global Problems: Counterfeiting on an International Level
The importation of medicine, weaknesses in the economy, and reductions in 
health benefits have contributed to the rise in counterfeiting.25 Counterfeiting is a bigger 
problem in developing countries and national measures alone have not been proven 
adequate to combat this activity.26  International measures are necessary to combat this 
growing threat.  In April 1999, 771 cases of substandard medicines entered into WHO 
database, 77% from developing countries.27 According to the World Health 
Organization, more than 10% of medicine on the global market is counterfeit with nearly 
25% of the medicine in developing countries being counterfeit or substandard.28  This 
21
 Id.
22
 Id.
23
 WHO Media Centre, supra note 17.
24 Id.
25
 Pfizer, Counterfeit Q & A, available at 
http://www.pfizer.com/subsites/counterfeit_importation/mn_faq_counterfeiting.html (last visited on May 
10, 2005)[hereinafter known as Pfizer Q & A].
26
 WHO Regional Office, supra note 15.
27
 WHO Media Centre, supra note 17.
28
 World Health Organization, Western Pacific Region, Rapid Alert System: Combating Counterfeit 
Medicines, available at http://218.111.249.28/ras/default.asp?tag=19& (last visited on July 14, 2005).
8number may be even larger since experts have estimated 60% of developing countries 
medicines are counterfeit.29
The consequences of counterfeit medicines are deadly.  The results range from 
therapeutic failure to drug resistance to death. When the 1995 meningitis epidemic broke 
out in Niger, 50,000 people where inoculated with fake vaccines which caused 2,500 
deaths.30 In 1995, cough syrup prepared with diethylene glycol, a toxic chemical used in 
antifreeze led to 89 deaths in Haiti and 30 infant deaths in India in 1998.31 A study 
conducted in South-East Asia in 2001 revealed that 38% of 104 anti-malarial drugs on 
sale in pharmacies did not contain any active ingredients and had resulted in a number of 
preventable deaths.32
China is widely regarded as the world leader in terms of manufacturing and 
exporting counterfeit products.33 In 2001, 192,000 Chinese people died due to fake 
drugs.34  Since 2001, Johnson & Johnson have built 38 criminal cases against Chinese 
factories that manufactured copies of its products.35
B.  Counterfeit Medicines Harm the United States 
Why is counterfeiting medicine even a problem in the United States?  The U.S. is 
an industrialized and modern country and has an entire Department of Health and Human 
29 International AntiCounterfeiting Coalition, White Paper: The Negative Consequences of International 
Intellectual Property Theft: Economic Harm, Threats to the Public Health and Safety, and Links to 
Organized Crime and Terrorist Organizations (January 2005) available at www.iacc.org/WhitePaper.pdf 
(last visited on June 28, 2005) [hereinafter known as White Paper] (citing The Engineer, Fighting the 
Fakers, at 16 (April 26, 2002); Phillippe Broussard, Dangerous Fakes, World Press Review, v44, n1, p36 
(1) (January 1999)).
30 WHO Media Centre, supra note 17.
31
 Id.
32
 Id.
33 White Paper, supra note 29 (citing China’s Killer Headache: Fake Pharmaceuticals, Washington Post 
(August 30, 2002)).
34
 White Paper, supra note 29.
35
 Id. 
9Services dedicated to keeping U.S. citizens safe with the creation of the Food and Drug 
Administration (FDA). However, over the years, counterfeit medicine has crept into our 
borders through reimportation.36 The amendment attempts to open the border doors even 
further by allowing increased importation of medicine.  However, the risks are high to 
public health, the economy, and to U.S. safety against terrorism.
1. Public Health
In 2004, The FDA’s Office of Criminal Investigations (OCI) initiated 58 cases of 
counterfeit drugs compared to 30 cases in 2003.37 Although the FDA believes the U.S. 
drug supply is one of the safest in the world, they agree that more work needs to be done 
to secure the national drug supply.38
Each year, U.S. citizens fill more than three billion prescriptions through 
pharmacies they believe are reputable and assume their medicine is safe.39 In 2001, 
Americans spent an estimate $140.6 billion on outpatient prescription drugs40.  However, 
as the following examples show, patients do not always get what they need.
In May 2003, the FDA alerted U.S. consumers that approximately 200,000 bottle s 
of counterfeit Lipitor, a medicine for patients with high cholesterol levels, were on the 
36
 LillyAnswers, Needy seniors don’t have to buy medications from other countries, available at 
http://www.lillyanswers.com/en/drug_issues.html (last visited on July 27, 2005)[hereinafter LillyAnswers]. 
37
 U.S. Food and Drug Administration, Combating Counterfeit Drugs: A Report of the Food and Drug 
Administration Annual Update (May 18, 2005), available at 
http://www.fda.gov/oc/initiatives/counterfeit/update2005.html (last visited on July 27, 2005)[hereinafter 
known as FDA Update 2005].
38
 Id.
39
 Katherine Eban, Dangerous Doses: How Counterfeiters Are Contaminating America’s Drug Supply pg 1-
10 (2005)[hereinafter Dangerous Doses].
40
 Silker, supra note 7.
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market.41  To date, eight people have been indicted and four have pled guilty while 
another was convicted by a jury trial.42
In 2001, three people were arrested in Los Angeles for copying the packaging, the 
packaging inserts, and the lot numbers of Pfizer’s Viagra.43  In 2002, seven people and 
five companies in the U.S., China, and India were charged with selling fake Viagra via 
the Internet after undercover officers bought over 25,000 pills.44  One supplier even told 
an undercover agent that he could supply 2.5 million pills a month.  Some of the pills 
were smuggled into the U.S. by hiding them in stereo speakers and stuffed toys.45
In 2005, a California man pled guilty to illegal trafficking more than $5.6 million 
in fake Viagra tablets.46  Frank Fu Jen Huang, 58, admitted to importing counterfeit 
Viagra tablets manufactured in China. Customs officials intercepted four of his shipments 
with more than 30,000 pills.47  Huang sold some of the product to an associate, David 
Srulevitch, 55, who then resold the fake Viagra.48  After the shipments were seized, 
Huang and Srulevitch manufactured approximately 700,000 fake Viagra tablets in a 
California laboratory.49
41
 White Paper, supra note 18 (citing Peter Jaret, Fake Drugs, Real Threat, Los Angeles Times at F1 
(February 4, 2004)).
42
 FDA Update 2005 supra note 37.
43 White Paper, supra note 29 (citing Douglas Pasternak, Knockoffs on the Pharmacy Shelf, Counterfeit 
Drugs are Coming to America, U.S. News & World Report at 26 (June 11, 2001)).
44 White Paper, supra note 29 (citing Ridgely Ochs, Sounding Alarm on Counterfeit Drugs; FDA 
Investigating Recent Faking Drug Cases, New York Newsday, at 6 (June 12, 2002)).
45
 Id.
46
 San Gabriel Tribune, Sentencing Delayed in Fake Viagra Case (March 28, 2005), available at 
http://www.sgvtribune.com/Stories/0,1413,205~12220~2787232,00.html (last visited July 31, 2005).
47
 Id.
48
 Id.
49
 Id.
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In 2004, another man admitted to conspiracy to manufacture and import 
thousands of counterfeit Viagra pills into the U.S. from Beijing.50 He was sentenced to 
18 months in prison with 3 years probation and fined $6000.51
Many of the drugs used by U.S. citizens are lifestyle drugs such as Viagra.  
Unlike the manufacturer Pfizer’s Viagra, the generic Viagra has misled many people and 
is considered illegal by the FDA and potentially dangerous because it may contain 
inappropriate substances that at first have positive effects but then turn into severe 
consequences.52
Generic Viagra is not considered legal to sell or buy in the US and a web site 
offering “generic Viagra” or “generic sildenafil citrate” is illegal.53  Pfizer recommends 
that the only way to know a patient is receiving genuine medicine is to buy from a 
National Association of Boards of Pharmacy (NABP) Verified Internet Pharmacy 
Practice Sites (VIPPS) certified online pharmacy.54
Investigative journalist Katherine Eban’s book Dangerous Doses examines the 
lives of three U.S. patients who received fake drugs during the course of treatment for a 
transplant, cancer, and AIDS.55  One of those patients is Timothy Fagan, a 16 year-old 
living in New York, who received eight weeks of injections of what doctors thought to be 
the correct dose of Epogen after a liver transplant.56  The injections were given to treat 
50
 FDA Update 2005, supra note 37.
51
 Id.
52 American Viagra Pharmacies Online, What is Generic Viagra and the Difference between Pfizer Viagra 
and Generic Viagra?, available at http://www.american-viagra-pharmacies.com/genericviagra.html (last 
visited on July 19, 2005).
53
 Id.
54
 Pfizer Q & A, supra note 25.
55
 Dangerous Doses, supra note 39.
56
 Id.
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his anemia and raise his red blood cell count.57  However, over the course of his 
treatment, Fagan grew worse as he suffered from painful aches and spasms58.  The 
doctors treating Fagan were surprised to see that the 40,000 units of Epogen they 
prescribed were ineffective.  The reason for this was that the injections turned out to
contain only 2,000 units.59
2.  Terrorist/Organized Crime
Epogen was also at the center of another controversy when a criminal ring re-
labeled approximately 110,000 bottles of Epogen to give the appearance it contained
dosages of Procrit, a drug twenty times stronger than Epogen.  (WP) The Florida Bureau 
of Statewide Pharmaceutical Services estimated the counterfeiters profit at around $46 
million.60
Terrorists and organized crime groups have been pirating goods for years to raise 
money for their activities.  Both types of organizations need to create and maintain steady 
sources of funding and are attracted to counterfeiting since it can be financially rewarding 
and anonymous.61 Because of the low risk of prosecution and large profits, the FBI states 
that counterfeiting is an “attractive enterprise for organized crime groups.”62
57
 Id.
58
 Id.
59
 Id.
60 Office of Program Policy Analysis and Government Accountability (OPPAGA) an office of the Florida 
Legislature, Justification Review: Counterfeit and Diverted Drugs Threaten Public Health and Waste State 
Dollars (February 2003), available at http://www.oppaga.state.fl.us (last visited on May 18, 
2005)[hereinafter known as Justification Review].
61
 White Paper, supra note 29.
62
 See http://www.fbi.gov/hq/cid/fc/fifu/about/about_ipc.htm (last visited on May 19, 2005).
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The September 11, 2001 attacks on the World Trade Center cost roughly 
$500,000 to pull off the hijacking of two planes, around $26,000 per terrorist.63  This 
amount of money is not hard to get if one pirates any type of good, including medicine. 
Discs with pirated music found in Paraguay by investigators contained cards with images 
of the World Trade Center exploding and Osama Bin Laden.64  Though the monetary 
source of the September 11th attacks has not been traced, it is quite possible that terrorists 
looked to counterfeiting goods or medicines as a quick and easy way to fund their 
activities.
Terrorist groups have already profited from counterfeiting according to a 2003 
report stating the Irish Republican Army (IRA) has produced counterfeit Ivomec, a 
livestock anti-parasite drug, to get money for weapons.65  The lab that produced the fake 
drug was found in Florida and the fake labels were produced on a farm in Northern 
Ireland.66
All it takes is a terrorist group to start manufacturing and sending out a few 
rounds of legitimate medicine from a home-based laboratory with counterfeit labels.  
After the product has entered the market and the group has not been caught for fake 
labels, there is nothing to stop terrorists from slipping a deadly chemical into bottles of 
cough syrup or headache pills.  
63
 White Paper, supra  note 29 (citing Katherine Macklem, The Terror Crisis has Lit a Fire under Ottawa’s 
Lagging Anti-lanundering Effort, MacLean’s, October 22, 2001 at 62). 
64
 White Paper, supra note 29 (citing Statement of Iain Grant before the House International Relations 
Committee, Hearing on Intellectual Property Crimes: Are Proceeds from Counterfeited Goods Funding 
Terrorism (July 16, 2003) available at http://wwwc.house.gov/international_relations/108/88392.pdf (pg 
48-49) (last visited on August 1, 2005)). 
65
 White Paper, supra note 29 (citing Global Options, Inc. & Reconnaissance International Report, An 
Analysis of Terrorist Threats to America’s Medicine Supply at 66-67 & nn. 138-39 (2003)). 
66
 Id.
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To prevent something like this from happening, the U.S. must deter criminals 
with stiffer penalties.  Counterfeiters must know that there are dire consequences in 
manufacturing fake medicines.
3.  No Accountability
There is little deterrence for those who are involved in counterfeiting and selling 
fake medicine.  There are no uniform sentencing guidelines, and the ones in place need 
altering.67
In 2005, Stephen Lewis, who ran a fraudulent Internet pharmacy using drugs from 
an illegal San Diego operation, was sentenced to two years in jail and fined only $5,000 
for conspiracy to sell unapproved drugs and conspiracy to launder money.68 His wife 
Pamela Lewis was sentenced to serve five months in jail with five months of home 
detention and ordered to pay only a $2,000 fine for conspiracy to sell unapproved drugs.
69 The San Diego judge ordered the couple to forfeit their bank account holdings as well 
as the profit from selling their home, roughly $150,000.70
However, the website MyRxForLess, run by the Lewis’s, sold between $1 million 
and $2.5 million worth of medication in two years according to the U.S. Attorney’s 
67
 See FDA Update 2005, supra note 37 (Increased criminal penalties deter counterfeiting and more 
adequately punish those convicted.  Although increased criminal penalties would not affect FDA's 
regulatory framework for overseeing the U.S. drug supply, they would provide an added deterrent to 
criminals who work to counterfeit our citizens' medications. FDA has requested that the United States 
Sentencing Commission amend the sentencing guidelines to increase substantially the criminal penalties for 
manufacturing and distributing counterfeit drugs and to provide for enhanced penalties based on the level 
of risk to the public health involved in the offense).
68
 S.D. Judge Sentences Couple in Internet Pharmacy Case, by Sarah Skidmore, San Diego Union Tribune, 
available at http://www.signonsandiego.com/news/business/20050518-9999-1b18webrx.html (last visited 
May 18, 2005).
69
 Id.
70
 Id.
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Office.71 The website operated out of Lake Worth, Florida but claimed the medications 
were from a reputable Mexican pharmacy when in actuality, people who worked for 
Stephen Lewis bought the drugs in Mexico and mailed them to customers.72  San Diego 
resident Mark Kolowich, who ran his own illegal pharmaceutical business, assisted the 
couple’s business by shipping fake Viagra and Cialis to customers.73  Kolowich pled 
guilty to charges and was sentenced to 51 months in prison and was made to forfeit cash 
profits.74
4.  Economic
There are also economic ramifications of counterfeiting.  A weak economy has 
people looking elsewhere for money making ideas when the unemployment rate is up.  In 
1996, U.S. losses from counterfeiting and piracy in general were estimated by the 
International Trade Commission to be around $200 billion.75
There are high profits in counterfeiting, which creates a large loss of tax revenue
with New York City losing $1.03 billion in lost tax revenue in 2003 due to intellectual 
property theft.76
71
 Id.
72
 Id.
73
 Id.
74
 Id.
75
 White Paper, supra note 29 (citing S.Rep.No. 104-177, 104th Cong., 1st Sess. 1-2 (1995)).
76
  Thompson: Counterfeiting Costs NYC more than $1 Billion Annually, The New York City Office of the 
Comptroller Press Release (November 22, 2004), available at 
http://www.comptroller.nyc.gov/press/2004_releases/print/pr04-11-065.shtm (last visited on July 12, 
2005).
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IV.  Cheaper Alternatives: Why They Exist and Where
A.  United States Free Market 
The U.S. is a free market having no price controls.77 On the other hand, Canada 
and the numerous other countries Congress is allowing to import into the U.S. have 
implemented government-set prices on prescriptions.  If companies do not follow this 
government control, they are forced to pay fines or risk the revocation of intellectual 
property.78 Price controls affect the amount of new scientific ideas for medicine.  Until 
the 1970’s, Europe developed most of the world’s medicines.79 However, by 2003, the 
U.S. developed eight out of the world’s top 10 selling drugs.80
B.  Research and Development Costs
It costs more than $800 million and 10-15 years to bring a new medicine to 
market with most medicines being developed by private U.S. research-based 
pharmaceutical manufacturers, not government laboratories.81  In 2003, Pharmaceutical 
Research and Manufacturers of America member companies invested an estimated $33.2 
billion on research to develop new medicine- 17.7% of domestic sales.82  This research 
and development to sales ratio is higher than any other U.S. industry.83  Yet, there needs 
77
 LillyAnswers, supra note 36.
78
 Id.
79
 Id.
80
 Id.
81
 Pharmaceutical Research and Manufacturers of America: Intellectual Property, available at 
http://www.phrma.org/issues/intprop/ (last visited on July 27, 2005).
82
 Pharmaceutical Research and Manufacturers of America: Research and Development, available at 
http://www.phrma.org/issues/researchdev/ (last visited on July 27, 2005).
83
 Id.
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to remain new research and development since new medicines help control health care 
costs.84
C.  Canadian Internet Pharmacies and Mexican Border Towns
Internet sales of pharmaceuticals make it easy for U.S. citizens to obtain 
inexpensive medicines, sometimes without a prescription.  There is a current trend in the 
U.S. for citizens to buy prescriptions from Internet websites claiming they are reputable 
Canadian pharmacies.  
There are several problems with this practice.  First and foremost, the drugs may 
still be counterfeit.85 In fact, the medicine can come from anywhere, since there are no 
guarantees that a website is actually based in Canada just because it claims to be.86
According to a report by GlobalOptions Inc., a security consulting firm, approximately 
1/3 of purported Canadian websites were actually not from a Canadian host.87  The U.S. 
FDA cannot guarantee the safety of Canadian medicine since importation of it increases 
the likelihood of altered or mishandled medicines reaching U.S. citizens.88  Lastly, 
medicines imported from Canada via the internet are also not subject to government 
health and safety checks.89
In 2003, the FDA and U.S. Customs and Border Protection conducted random 
searches of mailed pharmaceutical drugs into Miami, New York, and San Francisco.90
84
 Pharmaceutical Research and Manufacturers of America: Publications, available at 
http://www.phrma.org/publications/policy/24.04.2004.983.cfm (last visited on July 27, 2005).
85
 LillyAnswers, supra note 36.
86
 Id.
87 Id.
88
 Id.
89
 Before You Buy Canadian Drugs: What you need to know, available at http://www.BuySafeDrugs.info 
(last visited July 6, 2005).
90
 LillyAnswers, supra note 36.
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Of the 1,153 imported drugs, 88% were in violation of U.S. federal pharmaceutical safety 
or efficacy standards.91
The FDA also warns consumers against buying medicine in Mexican border 
towns since purchasers can not assume the products meet the “quality, efficacy, and 
safety standards of FDA authorized products or that FDA is assuring the quality, safety, 
and efficacy of products purchased from outside the United States.”92
V.  A Proposed Solution: The Amendment to the FTC Legislation
The sections above have laid out a basic sketch of what the global and national 
counterfeiting issues are.  The U.S. Congress has decided to take action to combat 
growing drug prices while still maintaining a safe pharmaceutical market for its citizens.  
The following section analyzes the amendment to determine whether the amendment
provides an adequate solution to the growing problem of counterfeit medicine.
A.   Explanation and Analysis of the Amendment
On July 21, 2005 Senators Bryon L. Dorgan (D-N.D) and Olympia Snowe (R-
ME) won approval by the Senate Commerce Committee on a 14-8 vote to allow an 
amendment to the FTC reauthorization bill .93  The amendment, previously known as 
S.334 Pharmaceutical Market Access and Drug Safety Act of 2005, is a bi-partisan 
attempt to address the issue of importing prescription drugs into the U.S.  Three 
91
 Id.
92
 U.S. Food and Drug Administration, FDA Talk Paper: FDA Warns Consumers About Counterfeit Drugs 
Purchased in Mexico, available at http://fda.gov/bbs/topics/ANSWERS/2004/ANS01303.html (last visited 
on May 18, 2005).
93
 News Release, Dorgan, Snowe Win Vote to Allow Re-Importation of Lower Priced Prescription Drugs, 
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provisions from separate bills (S.109) mandate that packages for reimported prescription 
drugs use counterfeit-resistant technologies and designate even more countries that can 
provide medicine to the U.S. if Canada restricts sales to the U.S.94 The amendment was 
introduced for a number of reasons but a main objective was to alleviate the costs of 
prescription drugs for U.S. citizens.95
1.  Importation from More Countries
The amendment allows U.S. licensed pharmacies and drug wholesalers to import 
medications approved by the FDA from Canada, 90 days after the amendment’s passage.  
Europe (nations that were members of the EU as of January 1, 2003), Australia, New 
Zealand, and Japan would be allowed to import one year after the bill’s passage date.96
This would then allow U.S. citizens to buy drugs from these countries and receive their 
discounted prices while still using a local U.S. pharmacy.97  However, allowing more 
medicine to enter into the country, since approximately 25 countries could import to the
U.S., increases the likelihood of fakes entering our healthcare system.  The exact path a 
medicine takes before it comes into the U.S. is often unknown.
Under the amendment, individuals can import prescription drugs for personal use 
and consumers can receive drugs via mail from Canadian pharmacies 90 days after its 
94
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enactment.98  Yet, as stated above , there is no way to guarantee these internet websites 
advertising as Canadian pharmacies are who they purport to be.  Further, there are no 
guarantees the medicine was not altered in some way before reaching a U.S. citizen’s 
doorstep.
2.  Safety Measures
The most important aspect the amendment lacks is adequate safety measures.
Congress must take a hard look at the serious lack of protection this amendment provides 
to the American people.
a.  Licensing/Registration
The proposed safety features of the amendment require pharmacies and drug 
wholesalers to register with the FDA.99 Exporters must give their name and identify all 
places of business that relate to qualifying drugs, including every warehouse or facility 
that is owned, controlled by, or operated for the exporter.100
The Secretary of Health and Human Services states the following requirements 
are necessary from a registrant exporter: inspection of facilities and the marking of 
compliant shipments, payment of fees, licensed as a pharmacist, conditions for individual 
importation, and maintenance of records and samples.101 The Secretary will provide a list 
98 Take Action Now for Fair Drug Prices! Comparison of S.184 and S.334, available at 
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of registered exporters, with contact information, through the FDA’s website and a toll 
free number.102
Pharmacists and wholesalers that reimport prescription drugs have to pay fees as 
much as 1% of the price of the medicine to fund the costs of federal inspectors and agents 
that will need to document the authenticity of the medicines entering the U.S.103
If the amendment passes, U.S. citizens will be able to order prescription drugs in 
the mail from Canadian pharmacies 90 days after the passage.104  With all the drugs 
coming in from Canada, there is impossible to inspect the shipments to make sure every 
single one of them are from registered exporters.  The amendment allows citizens to 
purchase drugs via the Internet from Canada, then from several other countries in the next 
year.  Once an exporter is registered under the amendment, the exporter is free to deliver 
medicine to U.S. citizens after paying a small fee.  Afterwards, there will be no stopping 
the flood of unregulated medicine entering into the country.
b.  Inspections
Exporters are subject to frequent, random inspections.105 However, even if an 
exporter’s place of business is inspected once a month, a producer of counterfeit can 
resume legitimate manufacturing while FDA inspectors are on the premises then start
producing fake pills once the inspectors leave the site.  In some cases, a foreign exporter 
102
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will have warning that a U.S. FDA representative is coming to visit their plant since word 
of mouth might put the exporter on notice.
The U.S. should retain the ability to have access to inspectors as witnesses in 
criminal cases and the amendment must be changed to allow the FDA the ability to 
inspect foreign establishments even where the FDA has instituted agreements with 
foreign regulatory agencies.  
c.  Chain of Custody
Importation of medicines must also have a “chain of custody” that allows the 
FDA to trace the medicine all the way back to a manufacturer that has been approved and 
inspected by the FDA.106 A chain of custody refers to the “combining (of) electronic and 
physical capabilities to create situational awareness about an item’s past and future as it 
moves through the supply chain.”107 This is necessary but the amendment does not 
establish how it will combat fraudulent paperwork or counterfeit pedigrees.  Fake 
paperwork is easy to create and the amendment fails to take a hard look at what 
technology is needed to provide a true and accurate chain of custody.
Under the amendment, pedigrees are not required when there are supposedly no
other intervening transactions from the manufacturer to the distributor.108 However, there 
are no guarantees that no intervening transactions occurred or even that the transaction 
paperwork is genuine.
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B.  Closing the Gaps of the Amendment
1.  Fixing the Problem Domestically
Instead of letting citizens go to other countries to find cheaper drugs, the U.S.
needs to seriously look at why its drug prices are so out of control.  There are no price 
controls.  There are no limits to what pharmaceutical manufacturers can charge for 
medicine in the U.S.  
Everybody can look for discounted prescription programs that are available to 
lower income families or individuals (such as http://www.rxassist.org/, 
http://www.peopleschoicerx.com/, or http://www.togetherrx.com/).
Starting January 1, 2006, Medicare will implement a prescription drug plan that 
will work for its users to help alleviate prescription costs and pay over half of patient’s 
drug costs.109 Local churches and charities will often help with prescription drug costs as 
well.  There are many ways for citizens to find discounts within the FDA approved U.S. 
borders without logging onto Canadian websites.
2. Funding
In order to fully regulate the practice of importing from this many countries, there 
needs to be adequate funding from the Secretary of Health and Human Services. It is 
unknown exactly how much is needed to create a system that is able to randomly inspect 
shipments from countries but some have suggested that the system would be fully 
financed by user fees of registered importers and Canadian exporters with fees capped at 
109
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1%.110  Still, meeting the FDA requirements to ship medicine into the U.S. will increase 
the discounted price.  Again, instead of spending money to inspect foreign drugs, pass on 
the discount to U.S. citizens on drugs they can buy within the country.
3.  No Criminal Deterrence for Foreign Companies
Other problems with the amendment include a weak framework of drug 
regulation with states and federal systems.  There are no criminal penalties when 
counterfeiting medicines occurs within U.S. borders and the financial incentives alone are 
enough to encourage a person to risk getting caught in exchange for making millions of 
dollars.  The WHO has noted that fear of arrest and prosecution and the leniency of penal 
sanction encourage counterfeiting even more.111 There are several problems associated 
with prosecuting companies shipping illegal drugs because prosecution is likely to 
involve extensive coordination between governments even if all of the countries involved
have developed legal systems.112  For prosecutions of foreign companies shipping illegal 
drugs into the U.S. and violating inspection standards, the U.S. must be able to a) gather 
evidence abroad b) gain the cooperation of witnesses in a foreign legal system who may 
face possible prosecution in their own countries c) produce competent evidence gathered 
abroad in a U.S. trial that demonstrates culpability beyond a reasonable doubt and d) 
overcome the legal barriers of jurisdiction and extradition so that the process can be 
executed.113
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Investigation of illegal actions abroad is difficult because grand jury subpoenas do 
not allow for service abroad except for citizens or residents of the United States.114  Yet, 
there are other ways to gather evidence such as letters rogatory or mutual legal assistance 
treaties.115  Letters rogatory are requests from a judge in the U.S. to the judiciary of a 
foreign country requesting the performance of an act, which if done without the sanction 
of the foreign court, would violate the country’s sovereignty.116  Mutual legal assistance 
treaties have the force of law and are faster and more reliable than letters rogatory.117
The amendment should be amended to reach criminal as well as jurisdictional 
powers over any foreign company and individuals who are allowed to import drugs into 
the United States.  Since the companies are subjecting themselves to U.S. standards and 
importation regulations, companies caught shipping illegal drugs should subject 
themselves to the law of the U.S.
4.  Lack of a Jurisdictional Section in the Amendment
When medicine is counterfeited and imported into the Congress has jurisdictional 
power to address the problem of counterfeit drugs when the conduct occurs overseas.  In 
international law, courts may use several legislative jurisdiction options including 
territorial, national, passive personality, protective, and universal jurisdiction.  However, 
Congress has not implemented a necessary jurisdictional section in the amendment that 
114
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would allow courts to prosecute.118 Congress must put in place a type of long arm statute 
to reach outside of U.S. borders to be able to prosecute violators of the amendment.
VI.  Real Solutions
A.  Improving Technology
It is imperative that new technologies are implemented to protect the U.S. drug 
supply and provide greater security to the general public.
1.  Tracking and Tracing with Electronic Pedigrees
Pedigrees are written sales history that traces each drug back to its initial 
manufacturer which provides an “audit trail” that should contain detailed information 
about each sales transaction.119 For example, each pedigree should contain the name and 
address of each purchaser of the drug.120  The Prescription Drug Marketing Act (PDMA) 
of 1987 established the requirement of pedigree papers as a minimum standard for the 
prescription drug wholesale industry to prevent drug diversion and counterfeiting.121  In 
the example of the criminal ring caught counterfeiting Procrit in Florida, the group resold 
the counterfeit drugs into the wholesale market with forged pedigree papers and passed 
the drugs through four states and four wholesalers.122  Forging papers are pretty simple.  
This is where electronic pedigrees come in.
Radiofrequency Identification (RFID) is the tagging of products by 
manufacturers, wholesalers, and retailers that provides reliable product tracking and 
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tracing.123 The FDA states that reliable RFID technology will make counterfeiting 
medicines extremely difficult or unprofitable and is the most promising approach to 
reliable product tracking and tracing.124 Studies have started to confirm that RFID will 
provide cost-reducing benefits in areas like inventory control.125  Supporters of RFID also 
hope that it will also provide the ability to track and trace the movement of every package 
of drugs from the production line to its distribution.126
RFID provides an electronic pedigree that surpasses the intent of PDMA and at a 
lower cost with the FDA stating more effective electronic pedigrees can be implemented 
within several years.127
2. Authentication Technologies
Authentication technologies such as color shifting inks, holograms, fingerprints, 
taggants, or chemical markers embedded in a drug or the label is an important part of an 
effective anti counterfeiting strategy.128 However, the FDA acknowledges that 
counterfeiters adapt quickly to roadblocks and the most effective use of authentication 
technology is to vary it by product over time.129
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3.  Additional Support
A national list has also been developed by the National Drug Advisory Coalition 
which includes 31 drugs that are mostly likely to be counterfeited that will also help in 
deterring counterfeiting.130
It is important to note that no single measure, not even electronic pedigrees, can 
provide adequate protection from counterfeiting.131 Technology must be rotated so that 
illegitimate manufacturers can not adapt and overcome anti-counterfeiting measures.  
B.  States and Stiffer Penalties
States license and regulate wholesale drug distributors currently.132  The FDA and 
National Association of Boards of Pharmacy (NABP) are currently developing Model 
Rules for Licensure of Wholesale Drug Distributors so that illegitimate wholesalers will 
find it difficult to become licensed and transact business, thus, making it easier to prevent 
counterfeit drugs from entering our system.133  Four states have laws in place similar to 
the Model Rules (California, Florida, Indiana, and Nevada) and other states are 
considering adoption (Iowa, New Jersey).134  The NABP also created the Verified-
Accredited Wholesale Distributors (VAWD) program to complement the Model Rules.135
Applicants for VAWD accreditation must undergo a criteria compliance review, licensure 
verification, an inspection, background checks, and screening through NABP’s 
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clearinghouse.136 This accreditation process provides assurances that wholesale 
distribution facilities are legitimate, validly licensed in good standing, and employ the 
best practices for safely distributing drugs from manufacturers.137
Increased criminal penalties are also necessary and provide an additional deterrent 
to counterfeiters and adequately punish convicted counterfeiters based on the level of risk 
to public health.138 Some states, like Florida, are recommending that state legislatures 
should raise criminal penalties involving counterfeit prescription drugs and drug 
diversion to second degree felonies.139 Strengthening accountability within the drug 
distribution system through tougher enforcement and stiffer penalties is another way to 
improve the situation.140 As stated previously, there shouldn’t be different penalties for 
forging a trademark and forging medicine.  Putting a fake drug on the market not only 
harms people but it undermines the entire healthcare system.
C.  Working Together:  Global Solutions to a Global Problem
Counterfeiting medicines that designed to help reduce the pain and suffering of 
patients is a growing problem.  However, this problem is not seen only in certain areas of 
the world.  Sick people live in every city, state, country, and continent so it is impossible 
for this not to be a global issue that must be addressed in a uniform manner across the 
world.
The WHO in the Western Pacific Region is working on a regional strategy calling 
for increased awareness of health care providers, policymakers, and the general public 
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through a regional rapid alert system as well as through stronger collaboration between 
medicine regulatory authorities and law enforcement agencies.141  The FDA has also 
stated their intentions to work with the WHO, Interpol, and other international public 
health and law enforcement organizations to develop and implement worldwide strategies 
to combat the problem of counterfeit drugs.142 In March 2005, representatives from the 
FDA attended a conference held by the Pan-American Health Organization (PAHO) 
where the FDA found its efforts to combat counterfeit drugs consistent with those of 
PAHO.143
The FDA’s Office of Criminal Investigations (OCI) trained foreign law 
enforcement, customs and judicial officers in the U.S. Patent and Trademark Office 
Intellectual Property Enforcement Academy on how to combat counterfeit drugs. (43)
It is essential that countries work together to combat the counterfeiting of 
medicine since it is such a global issue.  World leaders must make this a priority when 
setting national agendas since fake medicines continue to harm and even kill citizens of 
countries across the world.
D.  Consumer Awareness
Buy from VIPPS websites only, report suspected counterfeiting to 1-800-FDA-
1088 and to the manufacturer, watch out if the price of medicine seems too good to be 
true, do not buy from online pharmacies that offer to sell medication without 
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prescriptions, talk to your pharmacist if you notice anything different about your 
medicine or its effects on you.144
VII.  Conclusion
The amendment is the solution our lawmakers have come up with to try to solve 
the problem of high drug prices.  But in doing so, they have actually heightened the risk 
of creating an unsafe medicine supply.
There are so many examples of counterfeit medicines that have been either 
imported into the U.S. or manufactured within U.S. borders.  Before we start opening the 
doors to allow other countries to import prescription medicine, the country needs to first 
address the current state of affairs.  Why do we need to open the country up to more 
counterfeit drugs?  Some argue because they are cheaper than ours.  So, why not make 
U.S. pharmaceuticals affordable?  Others would then argue that research and 
development would suffer since the U.S. is the major contributor to R & D costs.  One 
must weigh the pros and cons.  The pros- the availability of cheap drugs, people can 
remain healthy or benefit from prescriptions when they are able to afford the medicine 
they need.  The cons- the risks of receiving a fake medicine include not getting the 
miracle of the miracle drugs because there are no active ingredients, aggravated 
symptoms, or even death.  Other risks include economic harm and terrorists possibly 
tainting the drug supply.
In the end, the fact remains that counterfeit drugs have been and will continue to 
harm people in the U.S. and abroad.  It is up to Congress to decide when the amendment
144 Pfizer Q & A, supra note 25.
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comes up for a vote, whether the proposed the amendment is enough protection to keep 
us safe.
